What We Can Learn from Underperforming Clinical Trial Sites

Introduction: Why Underperformance Deserves Serious Review

While much attention is given to high-performing clinical trial sites, underperforming sites hold equally valuable insights. Whether it’s delays in startup, failure to enroll, data quality issues, or protocol non-compliance, these sites represent high-risk nodes that impact trial timelines, regulatory confidence, and overall study cost. Reviewing lessons from past site underperformance is critical for enhancing feasibility planning, refining site selection SOPs, and building future-ready oversight systems.

In this article, we examine key patterns of site underperformance, common root causes, and how sponsors and CROs can integrate these findings into performance scoring systems and qualification frameworks.

1. Defining Underperformance in Clinical Trial Sites

Underperformance refers to a site’s inability to meet one or more of the following performance expectations:

• Timely site activation and study startup
• Subject enrollment goals within protocol-defined timeframes
• Compliance with GCP and protocol procedures
• Reliable and timely data entry and query resolution
• Retention of subjects through trial completion
• Readiness and cooperation during audits and inspections

A site failing in any of these dimensions may generate delays, require excessive oversight, or pose inspection risks—ultimately undermining trial quality.

2. Common Characteristics of Underperforming Sites

Data across studies reveal that poor-performing sites often share a set of recurring features:

• Delayed IRB submission or contract finalization
• Frequent staffing changes, especially untrained coordinators
• Lack of PI engagement in subject recruitment and monitoring
• High screen failure rates without justification
• Protocol deviations from dosing, visit windows, or assessments
• Low or stagnant enrollment after SIV
• Multiple unresolved queries at database lock
• Negative CRA feedback across multiple monitoring visits

Sites with three or more of these attributes in prior studies are often placed on performance watchlists or excluded from future site rosters.

3. Root Causes Behind Poor Site Performance

Sponsors and CROs often conduct root cause analyses (RCA) post-study to identify why a site underperformed. Common causes include:

• Over-commitment: Site accepted multiple concurrent studies beyond capacity
• Weak prescreening processes: High screen failure rates
• Lack of training: Protocol misunderstood by sub-investigators
• Infrastructure gaps: Missing equipment or storage issues
• Miscommunication: CRA and site coordinators not aligned
• Unrealistic feasibility submissions: Inflated subject availability claims

Identifying and documenting these root causes is essential for requalification decisions and future feasibility questionnaires.

4. Case Study: Site Startup Failure

In a global infectious disease study, Site 021 was selected based on a compelling feasibility response and previous participation in a similar Phase II trial. However:

• IRB approval took 76 days due to staff turnover
• SIV was delayed by 38 days due to contract amendments
• No subjects were enrolled after three months of activation
• CRA feedback flagged lack of engagement by the PI

Post-study RCA revealed the site had ongoing renovations that were not disclosed during the feasibility process. The site was removed from the active site list for subsequent protocols in the region.

5. Enrollment Metrics of Underperforming Sites

Enrollment data is a clear performance indicator. Sites performing below expected recruitment rates contribute to costly timeline extensions and amendments. Consider the table below:

Site C enrolled zero subjects due to internal prioritization of another trial and was closed before midpoint. Benchmarking these data points supports proactive feasibility filtering.

6. Regulatory Risks and Audit Flags from Low-Performing Sites

Underperforming sites are more likely to be cited during audits and inspections. Findings may include:

• Incomplete informed consent forms
• Improper temperature monitoring for IP
• Backdated source documents
• Untrained staff conducting assessments

Regulators such as the FDA and EMA expect sponsors to monitor site performance and take corrective actions. Failure to exclude or retrain poor sites may expose the sponsor to inspection findings.

7. Integrating Underperformance Lessons into Feasibility Models

Sponsors and CROs can build learnings from underperformance into feasibility and selection SOPs:

• Require documented PI involvement in prior studies
• Track screen failure and dropout rates over time
• Use performance dashboards with risk scores
• Flag unrealistic feasibility questionnaire responses
• Conduct pre-qualification site audits where prior risk exists

Tip: Create a “Do Not Engage” list for sites that have failed in two or more studies within a 3-year window—backed by objective performance data.

8. Using CTMS and Dashboards to Monitor for Decline

Tools such as Clinical Trial Management Systems (CTMS) and risk-based monitoring dashboards can flag performance deterioration in real time. Common alerts include:

• Enrollment drop-off
• Escalating deviation trends
• Delayed data entry or unresolved queries
• Staff turnover flags in CRA visit notes

Such systems allow proactive interventions or withdrawal decisions before site issues affect study timelines.

Conclusion

Underperforming clinical trial sites not only disrupt timelines and budgets—they compromise data quality and expose sponsors to regulatory scrutiny. By systematically capturing and analyzing the patterns and causes of site underperformance, sponsors and CROs can improve feasibility processes, strengthen qualification SOPs, and focus trial activities on the most capable, committed, and compliant partners. Lessons from failure are not setbacks—they are critical steps toward future trial success.

Comprehensive Checklist to Evaluate Clinical Site Capabilities

Introduction: Why Site Capability Assessment Matters

Evaluating site capabilities is a critical component of clinical trial feasibility and site selection. Regulatory authorities, including the FDA and EMA, expect sponsors and CROs to assess and document a site’s ability to conduct the trial in accordance with protocol, GCP guidelines, and regulatory requirements. An incomplete or rushed site capability assessment can lead to trial delays, protocol deviations, and inspection findings.

To ensure selection of high-performing and inspection-ready sites, sponsors should follow a standardized checklist that evaluates infrastructure, staffing, documentation practices, regulatory readiness, and digital capabilities. This article outlines a detailed, regulatory-compliant checklist and explains how each item contributes to overall trial success.

Core Domains in a Site Capability Checklist

The checklist for site capability assessment typically includes the following key domains:

• Infrastructure & Equipment
• Staffing & Oversight
• GCP Training & Certification
• Regulatory & IRB Preparedness
• SOP Availability & Version Control
• Digital Systems & Data Capture
• Prior Trial Performance & Protocol Compliance

Below is a sample site capability checklist structure that can be used during feasibility visits or remote evaluations.

Sample Checklist for Site Capability Assessment

Assessment Area	Checklist Item	Response
Infrastructure	Dedicated clinical trial space available?	Yes / No
Equipment	-20°C and -80°C storage with backup power?	Yes / No
Staffing	Study Coordinator assigned and CV available?	Yes / No
PI Oversight	PI available for at least 50% of trial visits?	Yes / No
Training	GCP certifications updated within 24 months?	Yes / No
SOPs	Site-specific SOPs for IP handling, AE reporting?	Yes / No
Systems	EDC/eCRF access and trained staff?	Yes / No

This checklist should be adapted to match the protocol complexity and therapeutic area. For example, in vaccine trials, cold-chain monitoring and mass screening areas are essential; for oncology trials, imaging infrastructure and emergency care facilities must be verified.

Infrastructure and Facility Readiness

A capable site must demonstrate access to secure, well-maintained facilities that ensure patient safety and data integrity. Specific checklist components include:

• Secure drug storage room (temperature monitored, restricted access)
• Exam rooms for confidential patient interaction
• Phlebotomy area with centrifuge and sample processing bench
• Archival area for essential documents (ALCOA-compliant)
• Generator backup for freezers and refrigerators

Equipment must be validated, calibrated, and accompanied by documentation such as:

• Calibration certificates (within 12 months)
• Preventive maintenance logs
• Power backup duration (e.g., 6–8 hours minimum)

Transitioning to Staffing, Oversight, and Regulatory Compliance

Infrastructure alone is not sufficient—qualified personnel, oversight mechanisms, and regulatory preparedness are critical to site capability. The next section will explore how to assess staffing models, PI engagement, and readiness for audits or inspections.

Staffing, Oversight, and PI Commitment

Staffing adequacy and PI involvement are major determinants of site performance. Regulatory agencies have cited inadequate PI oversight in numerous inspection reports. Key checklist elements in this domain include:

• PI has less than 3 active trials under current management
• Dedicated study coordinator and backup staff available
• PI has at least 5 years of experience in the relevant therapeutic area
• Site has a defined escalation plan for medical emergencies
• Delegation log maintained and up-to-date

Sites with high staff turnover or part-time study teams should be flagged for risk. Investigator workload should also be considered when evaluating capacity for protocol adherence and data quality.

Training and GCP Compliance

GCP training is not just a formality—it’s a regulatory requirement. The sponsor should verify:

• GCP training certificates for all key personnel (dated within past 2 years)
• Site-specific training on protocol, eCRF, safety reporting
• Attendance logs and training material archives

For complex protocols, specialized training may be necessary, such as IRT system usage, SAE documentation, or central lab portal navigation. Training records should be filed in the site regulatory binder and reviewed during monitoring visits.

Regulatory and Ethics Committee Preparedness

Feasibility assessments must evaluate a site’s readiness for EC/IRB submissions and regulatory interactions. Key items:

• IRB/EC submission history and typical approval timelines
• Prior experience with regulatory authority inspections (FDA, EMA, CDSCO)
• Regulatory binder structure and filing practices
• Informed consent process SOP and patient version language availability

Sites operating under hospital-based IRBs may require more time for approvals, while private ECs often offer faster turnaround but must meet accreditation criteria.

SOPs and Essential Document Control

The presence of up-to-date, trial-specific SOPs is a strong indicator of trial readiness. Key SOPs to request and review:

• IP storage and accountability SOP
• AE and SAE reporting SOP
• Source documentation and data entry SOP
• Informed consent process

  You said:
  Strictly NO emojis. Rewrite
  ChatGPT said:

  Comprehensive Checklist to Evaluate Clinical Site Capabilities

  Introduction: Why Site Capability Assessment Matters

  Evaluating site capabilities is a critical component of clinical trial feasibility and site selection. Regulatory authorities, including the FDA and EMA, expect sponsors and CROs to assess and document a site’s ability to conduct the trial in accordance with protocol, GCP guidelines, and regulatory requirements. An incomplete or rushed site capability assessment can lead to trial delays, protocol deviations, and inspection findings.

  To ensure selection of high-performing and inspection-ready sites, sponsors should follow a standardized checklist that evaluates infrastructure, staffing, documentation practices, regulatory readiness, and digital capabilities. This article outlines a detailed, regulatory-compliant checklist and explains how each item contributes to overall trial success.

  Core Domains in a Site Capability Checklist

  The checklist for site capability assessment typically includes the following key domains:

  • Infrastructure and Equipment
  • Staffing and Oversight
  • GCP Training and Certification
  • Regulatory and IRB Preparedness
  • SOP Availability and Version Control
  • Digital Systems and Data Capture
  • Prior Trial Performance and Protocol Compliance

  Below is a sample site capability checklist structure that can be used during feasibility visits or remote evaluations.

  Sample Checklist for Site Capability Assessment

  Assessment Area	Checklist Item	Response
  Infrastructure	Dedicated clinical trial space available	Yes / No
  Equipment	-20°C and -80°C storage with backup power	Yes / No
  Staffing	Study Coordinator assigned and CV available	Yes / No
  PI Oversight	PI available for at least 50% of trial visits	Yes / No
  Training	GCP certifications updated within 24 months	Yes / No
  SOPs	Site-specific SOPs for IP handling and AE reporting	Yes / No
  Systems	EDC/eCRF access and trained staff	Yes / No

  This checklist should be adapted to match the protocol complexity and therapeutic area. For example, in vaccine trials, cold-chain monitoring and mass screening areas are essential. For oncology trials, imaging infrastructure and emergency care facilities must be verified.

  Infrastructure and Facility Readiness

  A capable site must demonstrate access to secure, well-maintained facilities that ensure patient safety and data integrity. Specific checklist components include:

  • Secure drug storage room (temperature monitored, restricted access)
  • Exam rooms for confidential patient interaction
  • Phlebotomy area with centrifuge and sample processing bench
  • Archival area for essential documents (ALCOA-compliant)
  • Generator backup for freezers and refrigerators

  Equipment must be validated, calibrated, and accompanied by documentation such as:

  • Calibration certificates (within 12 months)
  • Preventive maintenance logs
  • Power backup duration (e.g., minimum 6–8 hours)

  Transitioning to Staffing, Oversight, and Regulatory Compliance

  Infrastructure alone is not sufficient—qualified personnel, oversight mechanisms, and regulatory preparedness are critical to site capability. The next section will explore how to assess staffing models, PI engagement, and readiness for audits or inspections.

  You said:
  this is hardly 500 words
  ChatGPT said:
  Updated saved memory

  Thanks for pointing that out. I’ll now rewrite Article 11: Checklist for Assessing Clinical Site Capabilities to meet the required 1400+ word count in a single HTML block, continuing from where it was truncated and expanding each section with greater depth, additional tables, examples, and regulatory insights. Please wait a moment…

  Comprehensive Checklist to Evaluate Clinical Site Capabilities

  Introduction: Why Site Capability Assessment Matters

  Evaluating site capabilities is one of the most vital steps in ensuring that a clinical trial runs smoothly, adheres to Good Clinical Practice (GCP), and meets regulatory expectations. Regulatory authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Indian CDSCO emphasize documentation of site readiness and performance history during inspections. A structured and comprehensive site capability checklist can mitigate trial risks, optimize resources, and prevent costly delays caused by underperforming or non-compliant sites.

  This tutorial article presents a detailed checklist tailored for sponsors and CROs evaluating clinical research sites for activation. The goal is to ensure objective site selection based on critical capability domains including infrastructure, human resources, regulatory preparedness, technology systems, documentation practices, and past performance.

  1. Infrastructure and Facility Evaluation

  Proper infrastructure is foundational to clinical trial success. Sponsors must assess whether the site’s physical facilities can support protocol activities such as patient visits, drug storage, specimen processing, and data entry.

  Checklist Items:

  • Dedicated space for informed consent and clinical assessments
  • Secure storage area for investigational product (IP), with restricted access
  • -20°C and -80°C freezers with backup power supply
  • 24/7 emergency facilities (where protocol requires)
  • Validated centrifuges, ECG machines, and calibrated medical devices
  • Controlled access to document archival areas

  Documentation to review:

  • Calibration logs and preventive maintenance records (past 12 months)
  • Equipment validation reports
  • Temperature mapping for storage areas

  Sample Facility Compliance Table:

  Facility Requirement	Availability	Evidence Reviewed
  -80°C Freezer	Yes	Calibration Certificate (dated May 2025)
  Emergency Backup	Yes	Diesel Generator: 12-hour runtime
  Secure IP Room	Yes	Logbook + CCTV record

  2. Staffing and Investigator Oversight

  Qualified, adequately trained staff with sufficient availability is critical. Investigators must have therapeutic area experience and be able to dedicate time to patient oversight, data review, and protocol compliance.

  Checklist Items:

  • Principal Investigator (PI) CV and GCP certificate dated within 2 years
  • Dedicated study coordinator with past trial experience
  • Sub-investigators covering medical specialties (if protocol requires)
  • Backup staff plan (vacation, turnover, illness)
  • Delegation of duties log (DOL) updated and signed
  • PI involvement: able to attend 50–75% of key patient visits

  PI Oversight Risk Scoring Table:

  Criteria	Score
  More than 5 years experience in therapeutic area	High
  More than 5 concurrent studies	Medium
  No inspection findings in past 3 years	High
  Delegation log signed within last 30 days	High

  3. GCP Training and Protocol Familiarity

  Training documentation provides assurance that site staff understand their responsibilities. Sponsors should verify that all trial personnel have current GCP training and have completed protocol-specific education.

  Checklist Items:

  • GCP training for all team members within past 2 years
  • Training logs signed and dated for protocol, safety reporting, and EDC entry
  • Attendance records for SIV (Site Initiation Visit)
  • Specialized training for use of devices (e.g., ePRO, IRT, central labs)

  4. Regulatory and IRB/EC Preparedness

  Site capability is closely linked to their ability to navigate local regulatory approvals. Regulatory inefficiencies often delay site activation.

  Checklist Items:

  • History of IRB/EC approvals for similar trials
  • Typical EC submission-to-approval timeline
  • Experience with regulatory authority submissions (e.g., FDA, PMDA, CDSCO)
  • Archived documents from prior approvals
  • Availability of regulatory binder with templates (ICF, CVs, lab licenses, etc.)

  Example: If a site in India lists CDSCO approval within 30 days, the sponsor should request documentation of previous DCGI submissions to confirm feasibility.

  5. SOP Availability and Quality Systems

  Standard Operating Procedures (SOPs) are required to govern clinical operations at the site. Sponsors must confirm SOP coverage, last review dates, and alignment with protocol requirements.

  Checklist Items:

  • List of active SOPs (IP management, AE/SAE reporting, ICF process)
  • Version history and approval dates
  • Staff acknowledgment logs of SOP training
  • Corrective and Preventive Action (CAPA) SOPs (if prior audits conducted)

  6. Technology Readiness and Digital Systems

  Modern trials rely on digital platforms including EDC, eCOA, eConsent, IRT, and eTMF. Sponsors must evaluate a site’s ability to interact with these systems securely and efficiently.

  Checklist Items:

  • Availability of stable internet connection and IT support
  • Access to validated computers for trial data entry
  • Training records for EDC and IRT platforms
  • Experience using eConsent systems (if applicable)
  • Audit trails maintained for source data

  Sites unable to support real-time data entry or digital archiving may increase protocol deviation risk and delay data locks.

  7. Review of Past Performance and Inspection History

  Prior performance is a leading indicator of future compliance. Sponsors should evaluate enrollment metrics, data query resolution, protocol adherence, and previous inspection outcomes.

  Checklist Items:

  • Average enrollment per month in last 3 similar trials
  • Number of protocol deviations reported (with reasons)
  • Audit or inspection findings (FDA Form 483, EMA observations, MHRA issues)
  • Time to First Patient In (FPI) in recent studies

  Sample Past Performance Snapshot:

  Metric	Site A	Site B
  Avg. Monthly Enrollment	6	3
  Deviation Rate (%)	2.5%	6.8%
  Query Resolution (avg days)	2.1	4.5
  Last FDA Inspection	No findings	483 issued (documentation lapse)

  8. CAPA Follow-Up and Continuous Improvement

  If a site has been previously audited or inspected, it must show documented evidence of CAPA implementation. A strong quality culture indicates long-term reliability.

  Checklist Items:

  • CAPA plan signed by PI and quality lead
  • Implementation logs and evidence of retraining
  • Quality assurance audit schedule
  • Root Cause Analysis documentation for major deviations

  Conclusion

  A structured and well-documented site capability assessment ensures sponsors select sites that are operationally ready, technically competent, and regulatory compliant. By applying a standardized checklist across domains—ranging from infrastructure and staffing to regulatory readiness and digital systems—sponsors can mitigate risk, optimize timelines, and improve data integrity. This approach not only enhances study execution but also demonstrates diligence during audits and inspections. Site capability checklists should be regularly reviewed, customized per protocol, and integrated into feasibility SOPs as part of a sponsor’s quality management system.

  ]]> https://www.clinicalstudies.in/how-to-design-effective-site-feasibility-questionnaires-for-clinical-trials/ Tue, 10 Jun 2025 22:56:00 +0000 https://www.clinicalstudies.in/how-to-design-effective-site-feasibility-questionnaires-for-clinical-trials/ Read More “How to Design Effective Site Feasibility Questionnaires for Clinical Trials” »

  ]]>

  Designing Site Feasibility Questionnaires that Drive Successful Clinical Trial Site Selection

  A well-designed site feasibility questionnaire (SFQ) is essential for evaluating and selecting the right sites for clinical trials. The SFQ allows sponsors and CROs to collect critical operational, regulatory, and clinical information from potential sites to assess their suitability for a given study. This guide explains how to create effective, actionable feasibility forms that enable informed decisions during trial planning.

  Purpose of a Site Feasibility Questionnaire

  The site feasibility questionnaire serves as a foundational tool for:

  • Evaluating a site’s ability to comply with study protocols
  • Assessing site infrastructure, patient pool, and staff availability
  • Identifying regulatory, logistical, or operational challenges
  • Facilitating early communication between sponsor and investigator

  Core Components of a Site Feasibility Questionnaire

  1. Site and Investigator Information

  • Site name, address, and contact information
  • Principal Investigator (PI) qualifications and experience
  • GCP training certificates and prior trial participation

  2. Study Experience and Therapeutic Expertise

  • Experience with the specific indication or similar trials
  • Number of studies conducted in the last 2 years
  • Regulatory inspection history and outcomes

  3. Infrastructure and Equipment Availability

  • Availability of pharmacy, laboratory, and diagnostic facilities
  • Access to equipment required by the protocol (e.g., ECG, centrifuge)
  • EDC and internet capabilities for remote data entry

  4. Patient Population and Recruitment Capacity

  • Estimated number of eligible patients per month
  • Access to target patient population through internal or referral networks
  • Recruitment strategies used in past studies

  5. Operational Readiness

  • Site’s SOPs for trial conduct
  • Availability of dedicated study coordinators
  • Turnaround time for ethics committee (EC) and regulatory submissions

  Best Practices in Questionnaire Design

  1. Use Standardized Templates: Leverage validated templates from Pharma SOP templates or sponsor-provided forms to ensure uniformity.
  2. Design Study-Specific Sections: Include questions aligned with the protocol requirements such as number of blood draws, patient diary handling, or imaging capabilities.
  3. Include Objective and Subjective Responses: Use checkboxes, drop-downs, and rating scales, but also allow free-text for investigator comments.
  4. Keep It Concise: Limit the form to critical fields, ideally within 4–6 pages, to encourage completion.
  5. Digital Distribution: Utilize tools like REDCap, SurveyMonkey, or CTMS-integrated forms to capture responses electronically.

  How to Analyze Feasibility Responses

  Once responses are collected, sponsors and CROs should evaluate them against pre-defined feasibility criteria:

  • Protocol-specific capabilities
  • Patient recruitment projections
  • Site compliance history and audit results
  • Geographic diversity and regulatory ease

  Sites can be scored or ranked using feasibility algorithms embedded in CTMS or Excel-based scoring sheets.

  Common Pitfalls to Avoid

  • Asking too many generic questions that do not impact study execution
  • Failing to update the questionnaire for each study’s protocol
  • Not validating the accuracy of provided information through monitoring
  • Over-reliance on past performance without evaluating current capacity

  Example: Sample Questions for Oncology Trial Feasibility

  • How many lung cancer patients did you enroll in studies over the last 12 months?
  • Do you have access to on-site PET-CT imaging?
  • Is there an in-house pharmacy capable of handling cytotoxic agents?
  • Do you have GCP-certified backup investigators?
  • What is your average EC approval timeline?

  ICH-GCP and Regulatory Considerations

  As per EMA and USFDA guidance, sponsor site evaluations must be documented and auditable. Feasibility documentation is considered essential and should be retained within the Trial Master File (TMF).

  Alignment with Pharma GMP and GCP guidelines ensures that the selected sites meet international standards for ethical and scientific trial conduct. Refer to resources like StabilityStudies.in for best practices in clinical documentation.

  Conclusion

  Effective site feasibility questionnaires are vital for strategic site selection and trial success. By tailoring the SFQ to protocol needs and analyzing responses with a structured approach, sponsors can significantly improve recruitment timelines, data quality, and regulatory compliance. A robust feasibility process lays the foundation for a successful clinical trial lifecycle.

  ]]> https://www.clinicalstudies.in/how-to-design-effective-site-feasibility-questionnaires-for-clinical-trials-2/ Tue, 10 Jun 2025 12:12:00 +0000 https://www.clinicalstudies.in/how-to-design-effective-site-feasibility-questionnaires-for-clinical-trials-2/ Read More “How to Design Effective Site Feasibility Questionnaires for Clinical Trials” »

  ]]> Designing Site Feasibility Questionnaires that Drive Successful Clinical Trial Site Selection

  A well-designed site feasibility questionnaire (SFQ) is essential for evaluating and selecting the right sites for clinical trials. The SFQ allows sponsors and CROs to collect critical operational, regulatory, and clinical information from potential sites to assess their suitability for a given study. This guide explains how to create effective, actionable feasibility forms that enable informed decisions during trial planning.

  Purpose of a Site Feasibility Questionnaire

  The site feasibility questionnaire serves as a foundational tool for:

  • Evaluating a site’s ability to comply with study protocols
  • Assessing site infrastructure, patient pool, and staff availability
  • Identifying regulatory, logistical, or operational challenges
  • Facilitating early communication between sponsor and investigator

  Core Components of a Site Feasibility Questionnaire

  1. Site and Investigator Information

  • Site name, address, and contact information
  • Principal Investigator (PI) qualifications and experience
  • GCP training certificates and prior trial participation

  2. Study Experience and Therapeutic Expertise

  • Experience with the specific indication or similar trials
  • Number of studies conducted in the last 2 years
  • Regulatory inspection history and outcomes

  3. Infrastructure and Equipment Availability

  • Availability of pharmacy, laboratory, and diagnostic facilities
  • Access to equipment required by the protocol (e.g., ECG, centrifuge)
  • EDC and internet capabilities for remote data entry

  4. Patient Population and Recruitment Capacity

  • Estimated number of eligible patients per month
  • Access to target patient population through internal or referral networks
  • Recruitment strategies used in past studies

  5. Operational Readiness

  • Site’s SOPs for trial conduct
  • Availability of dedicated study coordinators
  • Turnaround time for ethics committee (EC) and regulatory submissions

  Best Practices in Questionnaire Design

  1. Use Standardized Templates: Leverage validated templates from Pharma SOP templates or sponsor-provided forms to ensure uniformity.
  2. Design Study-Specific Sections: Include questions aligned with the protocol requirements such as number of blood draws, patient diary handling, or imaging capabilities.
  3. Include Objective and Subjective Responses: Use checkboxes, drop-downs, and rating scales, but also allow free-text for investigator comments.
  4. Keep It Concise: Limit the form to critical fields, ideally within 4–6 pages, to encourage completion.
  5. Digital Distribution: Utilize tools like REDCap, SurveyMonkey, or CTMS-integrated forms to capture responses electronically.

  How to Analyze Feasibility Responses

  Once responses are collected, sponsors and CROs should evaluate them against pre-defined feasibility criteria:

  • Protocol-specific capabilities
  • Patient recruitment projections
  • Site compliance history and audit results
  • Geographic diversity and regulatory ease

  Sites can be scored or ranked using feasibility algorithms embedded in CTMS or Excel-based scoring sheets.

  Common Pitfalls to Avoid

  • Asking too many generic questions that do not impact study execution
  • Failing to update the questionnaire for each study’s protocol
  • Not validating the accuracy of provided information through monitoring
  • Over-reliance on past performance without evaluating current capacity

  Example: Sample Questions for Oncology Trial Feasibility

  • How many lung cancer patients did you enroll in studies over the last 12 months?
  • Do you have access to on-site PET-CT imaging?
  • Is there an in-house pharmacy capable of handling cytotoxic agents?
  • Do you have GCP-certified backup investigators?
  • What is your average EC approval timeline?

  ICH-GCP and Regulatory Considerations

  As per EMA and USFDA guidance, sponsor site evaluations must be documented and auditable. Feasibility documentation is considered essential and should be retained within the Trial Master File (TMF).

  Alignment with Pharma GMP and GCP guidelines ensures that the selected sites meet international standards for ethical and scientific trial conduct. Refer to resources like StabilityStudies.in for best practices in clinical documentation.

  Conclusion

  Effective site feasibility questionnaires are vital for strategic site selection and trial success. By tailoring the SFQ to protocol needs and analyzing responses with a structured approach, sponsors can significantly improve recruitment timelines, data quality, and regulatory compliance. A robust feasibility process lays the foundation for a successful clinical trial lifecycle.

  ]]>